Efficacy and Safety of an Everolimus- vs. a Mycophenolate Mofetil-Based Regimen in Pediatric Renal Transplant Recipients
2015 | Zeitschriftenartikel. Eine Publikation mit Affiliation zur Georg-August-Universität Göttingen.
Spring zu: Zitieren & Links | Dokumente & Medien | Details | Versionsgeschichte
Zitiervorschlag
Efficacy and Safety of an Everolimus- vs. a Mycophenolate Mofetil-Based Regimen in Pediatric Renal Transplant Recipients
Brunkhorst, L. C.; Fichtner, A.; Hoecker, B.; Burmeister, G.; Ahlenstiel-Grunow, T.; Krupka, K. & Bald, M. u.a. (2015)
PLoS ONE, 10(9) art. e0135439. DOI: https://doi.org/10.1371/journal.pone.0135439
Dokumente & Medien
Details
- Autor(en)
- Brunkhorst, Lena Caroline; Fichtner, Alexander; Hoecker, Britta; Burmeister, Greta; Ahlenstiel-Grunow, Thurid; Krupka, Kai; Bald, Martin; Zapf, Antonia; Toenshoff, Burkhard; Pape, Lars
- Zusammenfassung
- Introduction Data on the efficacy and safety of everolimus in pediatric renal transplantation compared to other immunosuppressive regimens are scarce. Patients/Methods We therefore performed a multicenter, observational, matched cohort study over 4 years post-transplant in 35 patients on everolimus plus low-dose cyclosporine, who were matched (1: 2) with a control group of 70 children receiving a standard-dose calcineurin-inhibitor-and mycophenolate mofetil-based regimen. Results Corticosteroids were withdrawn in 83% in the everolimus vs. 39% in the control group (p<0.001). Patient and graft survival were comparable. The rate of biopsy-proven acute rejection episodes Banff score >= IA during the first year post-transplant was 6% in the everolimus vs. 13% in the control group (p = 0.23). The rate of de novo donor-specific HLA antibodies (11% in everolimus, 18% in controls) was comparable (p = 0.55). At 4 years post-transplant, mean eGFR in the everolimus group was 56 +/- 33 ml/min per 1.73 m(2) vs. 63 +/- 22 ml/min per 1.73 m(2) in the control group (p = 0.14). Everolimus therapy was associated with less BK polyomavirus replication (3% vs. 17% in controls; p = 0.04), but with a higher percentage of arterial hypertension and more hyperlipidemia (p<0.001). Conclusion In pediatric renal transplantation, an everolimus-based regimen with low-dose cyclosporine yields comparable four year results as a standard regimen, but with a different side effect profile.
- Erscheinungsdatum
- 2015
- Status
- published
- Herausgeber
- Public Library Science
- Zeitschrift
- PLoS ONE
- ISSN
- 1932-6203
- Förderer
- Novartis Germany, Nuremberg, Germany